<DOC>
	<DOC>NCT00831779</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects of dapagliflozin on insulin sensitivity</brief_summary>
	<brief_title>Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Subjects with type 2 diabetes and inadequate glycemic control, defined as A1C ≥ 7.0 and ≤ 10.0% at the enrollment visit Subjects should have been receiving either metformin therapy OR metformin therapy AND one insulin secretagogue for at least 12 weeks prior to enrollment Cpeptide ≥ 1.0 ng/ml (0.34 nmol/l) BMI ≤ 45.0 kg/m2 Urine albumin to creatinine ratio (UACR) &gt; 1,800 mg/g (203.4 mg/mmol/Cr) Aspartate Aminotransferase (AST) &gt; 3X Upper limit of normal (ULN) Alanine aminotransferase (ALT) &gt; 3X ULN Serum Total Bilirubin &gt; 2 mg/dL (34.2 μmol/l) Serum Creatinine (Scr) ≥ 1.50 mg/dL (133 μmol/l) for men; SCr ≥ 1.40 mg/dL (124 μmol/l) for women Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>